Tech–9104: Effective, All Natural, OTC Ointment for Osteoarthritis – Licensing, Partnering, Acquisition Opportunity
Licensing, Strategic Partnership, Acquisition Opportunity for this patented natural product that has successfully passed Phase II and Phase III trials and is ready to be marketed in the USA.
This technology, offered for licensing, provides a novel and potentially non-toxic approach to treat a wide range of cancers using RNA Inhibitors.
These biocompatible, non-toxic nanospheres are 20-80 nm in size and due to their hydrophilc-hydrophobic nature, are ideally suited for encapsulating drugs.
Tech-9094a: Licensing Opportunity: Endotoxin-binding Compounds for Sepsis (Orphan Drug Approval Pending)
The company is likely to get an Orphan Drug Approval in Jan, 2020 for these unique molecules that provide effective treatment for sepsis (for which currently there is no treatment. A unique opportunity...